Cell kinetics: A prognostic marker in epithelial ovarian cancer

Citationsfrom the Literature the tumor seemed to correlate with malignancy. Among the simple ovarian cysts, 65 had a diameter over 10 cm but none of them was malignant. The one that was malignant had a diameter of approximately 5 cm. In conclusion, unilocular ovarian cyst seems to carry a very slight chance of malignancy even in women over the age of 40. Papillary vegetation on the cyst wall, a structure that can be seen by ultrasound, seems to be a serious sign. Cell kinetics: A prognostic marker in epitbelial ovarian cancer

Silvestrini R; Daidone MG; Bolis G; Fontanelli R; Landoni F; Andreola S; Colombi R Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan; ITA GYNECOL. ONCOL. 1989 35/l (U-19) The proliferative activities (‘H-thymidine labelling index, LI) of 72 primary ovarian cancers and 76 metastatic lesions from untreated patients were evaluated. Overall, median LI values for primary and metastatic lesions were similar (7.8 vs 7.0%), but cell kinetics significantly differed in metastases from different sites. The LI of the primary tumor was unrelated to pathologic stage and histology, but was significantly correlated with histologic grading (P = .014). The prognostic relevance of LI was assessed for 43 untreated patients at stage III-IV (90’?‘0with bulky residual disease), treated after staging laparotomy with five cycles of cisplatin or of carboplatin. For 19 patients the LI was determined for both primary tumor and metastases, for 15 for the primary, and for 12 for the metastatic lesions. Complete remission (CR) was unrelated to pretreatment LI, although a trend toward a higher rate of CR was observed with rapidly proliferating tumors. Patients with slowly proliferating primary tumors had a higher probability of 1.5-year survival than patients with rapidly proliferating tumors (83 vs 50%). The difference was even greater between patients with both primary and metastatic lesions proliferating slowly (100%) and patients with at least one (61%) or both lesions proliferating rapidly (6Oclro).Pretreatment LI was not predictive for survival in subgroups of patients who attained CR, but it was quite predictive for survival in patients responding only partially or not at all (90 vs 32%, P = 0.25). Localization of gonadotropin

binding sites in human ovarian

neoplasms

Nakano R; Kitayama S; Yamoto M; Shima K; Ooshima A Department of Obstetrics and Gynecology, Wakayama Medical College, Wakayamashi 640; JPN AM. J. OBSTET. GYNECOL. 1989 161/4 (905-910) The binding of human luteinizing hormone and human follicle-stimulating hormone to ovariate tumor biopsy specimens from 29 patients was analyzed. The binding sites for human luteinizing hormone were demonstrated in one tumor of epithelial origin (mutinous cystadenoma) and in one sex cord-stromal origin (theta cell tumor). The binding sites for human follicle-staining hormone was found in three tumors of epithelial origin (serous cystadenoma and mutinous cystadenoma) and in two of sex cord-stromal origin (theta cell tumor and theta-granulosa cell tumor). The surface-binding

autoradiographic study revealed that the gonadotropins were localized in the stromal suggest that gonadotropic hormones may growth and differentiation of a certain type neoplasms.

85

binding sites for tissue. The results play a role in the of human ovarian

Serum levels of CA 125 and histological findings at secondlook laparotomy in ovarian carcinoma

Meier W; Stieber P; Eiermann W; Schneider A; Fateh-Moghadam A; Hepp H Department of Obstetrics and Gynecology, Klinikum Grosshadern, Ludwig-Maximilians-University Munich, 8000 Munchen 70; DELI GYNECOL. ONCOL. 1989 35/l (44-46) In a prospective study, the serum levels of CA 125 were estimated at regular intervals in 139 patients with ovarian carcinoma. Seventy-two of 78 patients with a second-look laparotomy had elevated CA 125 levels initially. The main aim of our investigation was the correlation of CA 125 levels with the histological findings at second-look laparotomy. A total of 26 patients were free from tumor. In each case CA 125 lay within the normal range. From the 46 patients where residual tumor was found, CA 125 levels were elevated in 23 cases, so that in 23 women with residual tumor, false negative levels were found. There were no false positive CA 125 levels. In all women with raised tumor marker levels at the time of the second-look laparotomy, tumor was found despite the often negative clinical or technical preoperative screening. A negative tumor marker at the time of the second look does not exclude residual tumor. For histological proof of complete remission, a second-look operation is imperative. If the CA 125 level is raised, the relevance of the planned second-look laparotomy is open to discussion. Role of an early second-look laparotomy in ovarian cancer

Van Lith JMM; Bouma J; Aalders JG; Boonstra H; Sleijfer DT; Willemse PHB Department of Gynecologic Oncology, University Hospital, 9713 EZ Groningen; NLD GYNECOL. ONCOL. 1989 35/2 (255-258) Of a group of 68 patients treated with standard polychemotherapy (CAP-5), 52 were evaluated by an early second-look laparotomy, preferably after three cycles of treatment. Of 21 patients with initial tumor residuals smaller than 2 cm, only 5 had residual tumor, and of 31 patients with tumor larger than 2 cm, 27 had residuals, which could be surgically debulked in 9 patients. Surgical evaluation led to termination of treatment in 6 patients with stable disease and to intensification of treatment in 5 younger patients with microscopic or bulky residuals. Thus, the second-look influenced therapeutic decisions and treatment policy in a total of 20 patients. The procedure went without severe complications for the duration of anesthesia; there was no difference between biopsy and debulking, but a larger amount of blood was lost during debulking surgery. Second-look laparotomy is well tolerated but should be performed only in selected cases, depending on the therapeutic options available. Int J Gynecol Obstet 32